Participants will complete self-questionnaires and have a standardized psychiatric evaluation at T2 ultrasound and at 2 months postpartum. conditions: Pregnancy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 140 type: ESTIMATED name: standardized clinical psychiatric evaluations name: self-administered psychiatric questionnaire assessments name: blood sampling measure: To determine the prevalence of the presence of at least one characterized psychiatric disorder, in remission or not, during pregnancy, at the time of the second-trimester ultrasound (T2 ultrasound) based on a standardized clinical assessment. measure: To determine the prevalence of each psychiatric disorder characterized during pregnancy at the time of the second-trimester ultrasound, based on a standardized clinical assessment. measure: Determine comorbidity profiles across all pathologies, describing whether there are patient groups based on these profiles. measure: Compare the prevalence of psychiatric disorders unknown to the obstetrics team with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound. measure: Compare the prevalence of psychiatric disorders unknown to the patient with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound. measure: Compare the prevalence of psychiatric disorders unknown to the general practitioner with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound. measure: Assess patients' medication compliance using self-administered questionnaires (MARS). measure: Assess patients' treatment beliefs using self-administered questionnaires (BMQ). measure: Determine the sociodemographic, psychological, psychiatric, medical and obstetric factors, as well as those associated with access to care and the care pathway associated with known or unknown diagnoses during pregnancy. measure: Determine the properties (sensitivity) of screening questionnaires (EPDS) for psychiatric disorders in this population. measure: Determine the properties (specificity) of screening questionnaires (EPDS) for psychiatric disorders in this population. measure: Determine the properties (positive predictive value) of screening questionnaires (EPDS) for psychiatric disorders in this population. measure: Determine the properties (negative predictive value) of screening questionnaires (EPDS) for psychiatric disorders in this population. measure: Determine the properties (sensitivity) of screening questionnaires ( MDQ) for psychiatric disorders in this population. measure: Determine the properties (specificity) of screening questionnaires ( MDQ) for psychiatric disorders in this population. measure: Determine the properties (positive predictive value) of screening questionnaires ( MDQ) for psychiatric disorders in this population. measure: Determine the properties (negative predictive value) of screening questionnaires ( MDQ) for psychiatric disorders in this population. measure: Determine the properties (sensitivity) of screening questionnaires (PCL-5) for psychiatric disorders in this population. measure: Determine the properties (specificity) of screening questionnaires (PCL-5) for psychiatric disorders in this population. measure: Determine the properties (positive predictive value) of screening questionnaires (PCL-5) for psychiatric disorders in this population. measure: Determine the properties (negative predictive value) of screening questionnaires (PCL-5) for psychiatric disorders in this population. measure: Determine the properties (sensitivity) of screening questionnaires (EDEQ) for psychiatric disorders in this population. measure: Determine the properties (specificity) of screening questionnaires (EDEQ) for psychiatric disorders in this population. measure: Determine the properties (positive predictive value) of screening questionnaires (EDEQ) for psychiatric disorders in this population. measure: Determine the properties (negative predictive value) of screening questionnaires (EDEQ) for psychiatric disorders in this population. measure: Compare mother-child bonding difficulties between patients with and without a psychiatric diagnosis at the time of the study, using scales (PAI). measure: Compare mother-child bonding difficulties between patients with and without a psychiatric diagnosis at the time of the study, using scales (MIBS). measure: Describe how the study will be carried out, either in person or by teleconsultation, and the reasons for this choice. measure: Determine the prevalence of each psychiatric disorder at two months post-inclusion based on a standardized clinical assessment. sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False